CSL's $11.7B buy­out hits an­titrust de­lay — is it a sign of what's to come?

CSL’s mam­moth Vi­for Phar­ma buy­out will have to wait a few more months, the com­pa­ny re­vealed on Wednes­day, as ex­perts won­der whether an­titrust reg­u­la­tors will slow things down across the en­tire in­dus­try.

While CSL pre­vi­ous­ly ex­pect­ed to close its $11.7 bil­lion Vi­for ac­qui­si­tion this June, the com­pa­ny said on Wednes­day that the reg­u­la­to­ry ap­proval process is tak­ing a bit longer than ex­pect­ed. Some an­titrust au­thor­i­ties have ap­proved the trans­ac­tion, but oth­ers re­main out­stand­ing, Vi­for said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER